Topical Therapies for Nonmelanoma Skin Cancers

  • Abel Torres
  • Tejas Desai


As the incidence of nonmelanoma skin cancer (NMSC) continues to rise, topical therapies will be used with increasing frequency. Topical therapies are currently being utilized as primary or adjunctive means of treating an array of NMSCs. Although surgical therapies, such as Mohs Micrographic Surgery (MMS), remain the mainstay for tumor removal, topical therapy provides an alternative treatment modality for some skin cancer patients as well as serving as a useful adjunct to surgery. Topical therapies may also increase overall efficacy by treating subclinical lesions and identifying asymmetrical growth of NMSCs. In some patients, such as high-risk surgical candidates, they can be used to avoid surgery altogether or to minimize the extent of surgery. Topical therapies may also be helpful in a diagnostic manner. In instances where biopsy sites are equivocal, topical therapies may facilitate tumor identification prior to surgery.


Allergic Contact Dermatitis Actinic Keratose Topical Therapy Nonmelanoma Skin Cancer Federal Drug Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002 Oct;27(7):571–577.PubMedCrossRefGoogle Scholar
  2. 2.
    Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008 Jan;27(2):190–199.PubMedCrossRefGoogle Scholar
  3. 3.
    Barnetson RC, Satchell A, Zhuang L, et al. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol. 2007 Feb;29:639–643.CrossRefGoogle Scholar
  4. 4.
    Wolf IH, Kodama K, Cerroni L, et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007 Jun;29(3):237–241.PubMedCrossRefGoogle Scholar
  5. 5.
    Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007 Jun;204(6):1441–1451.PubMedCrossRefGoogle Scholar
  6. 6.
    Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Nat Can Inst. 2005 Aug;97(15):1143–1153.CrossRefGoogle Scholar
  7. 7.
    Quatresooz P, Pierard GE. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin and Exp Derm. 2003 Aug;28(Suppl 1):27–29.CrossRefGoogle Scholar
  8. 8.
    Gaspari AA, Sauder D. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg. 2003;29:1027–1034. Review PMID: 12974699, Wiley-Blackwell.Google Scholar
  9. 9.
    Torres A, Storey L, Anders M, et al. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol. 2007;157:1132–1147.PubMedCrossRefGoogle Scholar
  10. 10.
    Metcalf SA, Crowson N, Naylor M, et al. Imiquimod as an antiaging agent. JAAD. 2007 Mar;56(3):422–425.Google Scholar
  11. 11.
    Smith K, Hamza S, Germain M, et al. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Derm Surg. 2007;33:1419–1429.Google Scholar
  12. 12.
    Wolverton SE. Comprehensive Dermatologic Drug Therapy. 1st ed. Philadelphia: Saunders Elsevier; 2001:529–530.Google Scholar
  13. 13.
    Schon MP, Schon M. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338–1347.PubMedCrossRefGoogle Scholar
  14. 14.
    Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis. 2004 May;9(3):291–298.PubMedCrossRefGoogle Scholar
  15. 15.
    Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980;208:516–518.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 1996;13:57–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Shousong C, Kun L, Toth K, et al. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, and oral 5-fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res. 1999;5:267–274.Google Scholar
  18. 18.
    Fujita M, Kuwano K, Kunitake R, et al. Endothelial cell apoptosis in lipopolysaccharide-induced lung injury in mice. Int Arch Allergy Immunol. 1998;117:202–208.PubMedCrossRefGoogle Scholar
  19. 19.
    Riedel F, Gotte K, Bergler W, et al. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck. 2000;22:183–189.PubMedCrossRefGoogle Scholar
  20. 20.
    Reddy KB, Hocevar BA, Howe PH. Inhibition of G1 phase cyclin dependent kinases by transforming growth factor beta 1. J Cell Biochem. 1994;56:418–425.PubMedCrossRefGoogle Scholar
  21. 21.
    Majewski S, Marczak M, Mlymarczyk B, et al. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol. 2005;44:14–19.PubMedCrossRefGoogle Scholar
  22. 22.
    Li VW, Li WW. Antiangiogenesis in the treatment of skin cancer. J Drugs Dermatol. 2008;7(Suppl 1):17–24.Google Scholar
  23. 23.
    Sidky Y, Borden E, Weeks C, et al. Inhibition of murine tumour growth by an interferon inducing imidazoquinolinamine. Cancer Res. 1992;52:3528–3533.PubMedGoogle Scholar
  24. 24.
    Medonca CO, Yates VM. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol. 2006;31:721.CrossRefGoogle Scholar
  25. 25.
    Al-Dujaili Z, Hsu S. Imiquimod-induced vitiligo. Dermatol Online J. 2007 May 1;13(2):10.PubMedGoogle Scholar
  26. 26.
    Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Acad Dermatol. 2005;52(4):715–716.CrossRefGoogle Scholar
  27. 27.
    Senel E, Seckin D. Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol. 2007 Nov–Dec;73(6):423.PubMedCrossRefGoogle Scholar
  28. 28.
    Stefanki C, Nicolaidu E, Hadjivassilou M, et al. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venerol. 2006 Jul;20(6):755–756.CrossRefGoogle Scholar
  29. 29.
    Campagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obst Gynecol Reprod Bio. 2003;109:224–227.CrossRefGoogle Scholar
  30. 30.
    Chakrabarty AK, Mraz S, Geisse JK, et al. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. JAAD. 2005 Feb;52(2 Suppl 1):35–37.Google Scholar
  31. 31.
    Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004 Jul;140(7):889–890.PubMedCrossRefGoogle Scholar
  32. 32.
    Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol. 2005 Jul;141(7):908–909.PubMedCrossRefGoogle Scholar
  33. 33.
    Marty CL, Randle HW, Walsh JS. Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatol Surg. 2005 Jul;31(7 Pt 1):780–782; discussion 782–783.PubMedGoogle Scholar
  34. 34.
    McQuillan O, Higgins SP. Acute urinary retention following self-treatment of genital warts with imiquimod 5% cream. Sex Transm Infect. 2004 Oct;80(5):419–420.PubMedCrossRefGoogle Scholar
  35. 35.
    Fanti PA, Dika E, Vaccari S, et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol. 2006 Dec;45(12):1464–1465.PubMedCrossRefGoogle Scholar
  36. 36.
    Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004 Dec;140(12):1490–1495.PubMedCrossRefGoogle Scholar
  37. 37.
    Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol. 2006 Jan;31(1):140–141.PubMedCrossRefGoogle Scholar
  38. 38.
    Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol. 2004 May;45(2):123–124.PubMedCrossRefGoogle Scholar
  39. 39.
    Taylor CL, Maslen M, Kapembwa M. A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect. 2006 Jun;82(3):227–228.PubMedCrossRefGoogle Scholar
  40. 40.
    Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. NZ Med J. 2005 Oct;118(1223):1–4.Google Scholar
  41. 41.
    De Berker D, Marren P, Powell SM, et al. Contact sensitivity to the stearyl alcohol in Efudix® cream (5-fluorouracil). Contact Dermatitis. 1992;26:138.PubMedCrossRefGoogle Scholar
  42. 42.
    Farrar CW, Bell HK, King CM. Allergic contact dermatitis from propylene glycol in Efudix®. Contact Dermatitis. 2003;48:345.PubMedCrossRefGoogle Scholar
  43. 43.
    Goette DK, Odom RB. Allergic contact dermatitis to topical fluorouracil. Arch Dermatol. 1977;113:1058–1061.Google Scholar
  44. 44.
    Meijer BUGA, de Waard-van der Spek FB. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix® cream). Contact Dermatitis. 2007;57:58–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Tennstedt D, Lachapelle JM. Allergic contact dermatitis to 5-fluorouracil. Contact Dermatitis. 1987;35:124–125.Google Scholar
  46. 46.
    Yesudian PD, King CM. Allergic contact dermatitis from stearyl alcohol in Efudix® cream. Contact Dermatitis. 2001;45:313–314.PubMedCrossRefGoogle Scholar
  47. 47.
    Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer. 1991;68(3):499–501.PubMedCrossRefGoogle Scholar
  48. 48.
    Johnson MR, Hageboutros A, Wang K, et al. Life threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006–2011.PubMedGoogle Scholar
  49. 49.
    Takimoto CH, Lu Z-H, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–481.PubMedGoogle Scholar
  50. 50.
    Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985;313(4):245–249.PubMedCrossRefGoogle Scholar
  51. 51.
    “Efudix®”. In: “Dictionnaire Vidal” OVP Editions du Vidal, Paris, Thérapeutique dermatologique, Médecine-Sciences Flammarion, 2001:694.Google Scholar
  52. 52.
    Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Accessed Jan 9, 2009.
  53. 53.
    Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDS). Br J Dermatol. 2007 May;156(Suppl 3):25–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Kerr OA, Kavanagh G, Horn H. Allergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2002 Sep;47(3):175.PubMedCrossRefGoogle Scholar
  55. 55.
    Kleyn CE, Bharati A, King CM.Contact dermatitis from 3 different allergens in Solaraze® gel. Contact Dermatitis. 2004;51(4):215–216.Google Scholar
  56. 56.
    Valsecchi R, Pansera B, Leghissa P, et al. Allergic contact dermatitis of the eyelids and conjunctivitis from diclofenac. Contact Dermatitis. 1996 Feb;34(2):150–151.PubMedCrossRefGoogle Scholar
  57. 57.
    Kowalzick L, Ziegler H. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2006 Jun;54(6)348–349.PubMedCrossRefGoogle Scholar
  58. 58.
    Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol. 2007 Sep;57(3):484–502.PubMedCrossRefGoogle Scholar
  59. 59.
    Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–141.PubMedCrossRefGoogle Scholar
  60. 60.
    Jorizzo J, Dinehart S, Matheson R, et al. Vehicle controlled, double blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007 Aug;57(2):265–268.Google Scholar
  61. 61.
    Hadley G, Derry S, Moore R. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251–1255.Google Scholar
  62. 62.
    Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis. Arch Dermatol. 2005 Apr;141:467–473.PubMedCrossRefGoogle Scholar
  63. 63.
    Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714–721.Google Scholar
  64. 64.
    Persuad AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. JAAD. 2002 Oct;47(4):553–556.Google Scholar
  65. 65.
    Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002 Oct;47(4):571–577.Google Scholar
  66. 66.
    Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002 Nov;138:1498–1502.PubMedCrossRefGoogle Scholar
  67. 67.
    Szeimes R, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004 Oct;51(4):547–555.Google Scholar
  68. 68.
    Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett. 2001 Jun;6(9):1–4.PubMedGoogle Scholar
  69. 69.
    Jury CS, Ramraka-Jones VS, Gudi V, et al. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol. 2005 Oct;153(4):808–810.PubMedCrossRefGoogle Scholar
  70. 70.
    Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002 Jun;24(6):990–1000.PubMedCrossRefGoogle Scholar
  71. 71.
    Robbins, P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol. 2002;1:25–30.Google Scholar
  72. 72.
    Simmonds WL. Double-blind investigation comparing a 1% vs 5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis. 1973;12:615–617.Google Scholar
  73. 73.
    Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1,2, or 4 weeks. Cutis. 2002 Aug;70(Suppl 2):22–29.PubMedGoogle Scholar
  74. 74.
    Fariba I, Ali A, Hossein SA, et al. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venerol Leprol. 2006 Sep–Oct;72(5):346–349.CrossRefGoogle Scholar
  75. 75.
    Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluron gel for the treatment of solar keratoses. Australas J Dermatol. 2003 Feb;44(1):40–43.PubMedCrossRefGoogle Scholar
  76. 76.
    Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004 Jul–Aug;3(4):401–407.PubMedGoogle Scholar
  77. 77.
    Pirard D, Vereecken P, Melot C, et al. Three percent diclofenac in 2.5% hyaluron gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005 Nov;297(5):185–189.PubMedCrossRefGoogle Scholar
  78. 78.
    Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002 Jan;146(1):94–100.PubMedCrossRefGoogle Scholar
  79. 79.
    Krawthcenko N, Roewert-Huber J, Ulrich M, et al. A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1 year follow up. Br J Dermatol. 2007;157 (Suppl 2):34–40.CrossRefGoogle Scholar
  80. 80.
    Tanghetti E, Werschler WP. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J. Drugs Dermatol. 2007 Feb;6(2):144–147.PubMedGoogle Scholar
  81. 81.
    Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005 Oct;9(5):209–214.PubMedCrossRefGoogle Scholar
  82. 82.
    Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007 Aug;6(8):778–781.PubMedGoogle Scholar
  83. 83.
    Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004 Jul;140(7):813–816.PubMedCrossRefGoogle Scholar
  84. 84.
    Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006 Feb;5(2):133–139.PubMedGoogle Scholar
  85. 85.
    Berlin J, Rigel D. A prospective double-arm, multicenter, open-label phase IV evaluation of the use of diclofenac sodium 3% gel in the treatment of AK lesions post-cryosurgery. J Am Acad Dermatol. 2007 Jan P2303 poster presentation.Google Scholar
  86. 86.
    Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008 Jan;7(1):23–25.PubMedGoogle Scholar
  87. 87.
    Kircik L, Earl M. Pharmacoeconomic evaluation of 5-fluorouracil for the treatment of actinic keratosis. J Am Acad Dermatol. 2007 Jan P2301 poster presentationGoogle Scholar
  88. 88.
    “Imiquimod”, last updated December 11, 2008.
  89. 89.
    Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002–1007.Google Scholar
  90. 90.
    Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007 Oct;57(4):616–621.Google Scholar
  91. 91.
    Ezughah FI, Dawe RS, Ibbotson SH, et al A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolg Treat. 2008;19(2):111–117.Google Scholar
  92. 92.
    Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May;50(5):722–733.Google Scholar
  93. 93.
    Huber A, Huber JD, Skinner RB, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open label series. Dermatol Surg. 2004;30:429–430.PubMedCrossRefGoogle Scholar
  94. 94.
    Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001 May;44(5):807–813.Google Scholar
  95. 95.
    Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol. 2007 May;6(5):507–513.PubMedGoogle Scholar
  96. 96.
    Schulze HJ, Cribler B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005 May;152(5):939–947.Google Scholar
  97. 97.
    Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol. 2002 Sep;138:1165–1171.PubMedCrossRefGoogle Scholar
  98. 98.
    Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004 Dec;30(12 Pt 1):1462–1469.PubMedCrossRefGoogle Scholar
  99. 99.
    Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227–1236.PubMedCrossRefGoogle Scholar
  100. 100.
    “5-fluorouracil”, last updated December 11, 2008.
  101. 101.
    Smitha P, Raghavendra R, Sripathi H, et al. Successful use of imiquimod 5% cream in Bowen’s disease. Indian J Dermatol Leprol. 2007 Nov–Dec;73(6):423–425.Google Scholar
  102. 102.
    Ondo Al, Mings SM, Pestak RM, et al. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006 Dec;55(6):1092–1094.Google Scholar
  103. 103.
    Thissen MR, Kuijpers DI, Krekis GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006 May;5(5):461–464.Google Scholar
  104. 104.
    Salasche SJ. Curettage and electrodessication in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol. 1983;8:496–503.Google Scholar
  105. 105.
    Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas, part 4: x-ray therapy. J Dermatol Surg Oncol. 1992;18:549–554.PubMedGoogle Scholar
  106. 106.
    Suhge d’Aubermont PC, Bennett RG. Failure of curettage and electrodessication for removal of basal cell carcinoma. Arch Dermatol. 1984;120:1456–1460.PubMedCrossRefGoogle Scholar
  107. 107.
    Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodessication for basal cell carcinoma: preliminary report. J Drugs Dermatol. 2008;7(Suppl 1):15–16.Google Scholar
  108. 108.
    Nercessian OA, Wu H, Nazarian D, et al. Intraoperative pacemaker dysfunction caused by the use of electrocautery during a total hip arthroplasty. J Arthroplasty. 1998;13:599–602.PubMedCrossRefGoogle Scholar
  109. 109.
    Levine PA, Balady GJ, Lazar HL, et al. Electrocautery and pacemakers: management of the paced patient subject to electrocautery. Ann Thoracic Surg. 1986;41:313–317.CrossRefGoogle Scholar
  110. 110.
    Snow JS, Kalenderian D, Clasacco JA, et al. Implanted devices and electromagnetic interference: case presentations and review. J Invasive Cardiol. 1995;7:25–32.PubMedGoogle Scholar
  111. 111.
    Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007 Sep;6(9):910–914.PubMedGoogle Scholar
  112. 112.
    Nelson CG, Spencer J, Nelson CG Jr. A single-arm, open label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol. 2007 July;6(7):712–717.PubMedGoogle Scholar
  113. 113.
    Ulrich C, Forschner T, Ulrich M, et al. Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol. 2007 May;156(Suppl 3):43–46.Google Scholar
  114. 114.
    Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol. 1977 July;113:906–908.PubMedCrossRefGoogle Scholar
  115. 115.
    Smith KJ, Germain M, Yeager J, et al. Topical 5% imiquimod for the therapy of actinic cheilitis. JAAD. 2002 Oct;47(4):497–501.Google Scholar
  116. 116.
    Biasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol. 2005 Dec;140(6):1136–1139.CrossRefGoogle Scholar
  117. 117.
    Choontanom R, Thanos S, Busse H, et al. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007 Mar;245:1217–1220.PubMedCrossRefGoogle Scholar
  118. 118.
    Leppala J, Kaarniranta K, Uuusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007 Aug;85(5):566–568.PubMedCrossRefGoogle Scholar
  119. 119.
    Galentine P, Sloas H, Hargett N, et al. Bilateral cicatricial ectropion following topical administration of 5-fluorouracil. Ann Ophthalmol. 1981 May;13(5):575–577.PubMedGoogle Scholar
  120. 120.
    Hecker D, Hacker SM, Ramos-Caro FA, et al. Temporary ectropion due to topical fluorouracil. Cutis. 1994 Mar;53(3):137–138.PubMedGoogle Scholar
  121. 121.
    Lewis JE. Temporary ectropion due to topical fluorouracil. Int J Dermatol. 1997 Jan;36(1):79.PubMedCrossRefGoogle Scholar
  122. 122.
    Poothullil AM, Colby KA. Topical medical therapies for ocular surface tumors. Semin Ophthalmol. 2006 Jul–Sep;21(3):161–169.PubMedCrossRefGoogle Scholar
  123. 123.
    Danielsen AG, Sand C, Weisman K. Treatment of Bowen’s disease of the penis with imiquimod 5% cream. Clin Exp Dermatol. 2003 Nov;28(Suppl 1):7–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Micali G, Nasca MR, Tedeschi A. Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin Exp Dermatol. 2003 Nov;28(Suppl 1):4–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Orengo I, Rosen T, Guill C. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol. 2002 Oct;47(4):225–228.Google Scholar
  126. 126.
    Goorney BP, Polori R. A case of Bowenoid Papulosis of the penis successfully treated with topical imiquimod cream 5%. Int J STD AIDS. 2004 Dec;15(12):833–835.PubMedCrossRefGoogle Scholar
  127. 127.
    Bernstein DI, Spruance SL, Arora SS, et al. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis. 2005 Sep 15;41(6):808–814. Epub 2005 Aug 10PubMedCrossRefGoogle Scholar
  128. 128.
    Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002 Apr;46(4):545–548.Google Scholar
  129. 129.
    Ferreres JR, Macaya A, Jucgla A, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877–878.PubMedGoogle Scholar
  130. 130.
    Micali G, Lacarrubba F, Nasca MR, et al. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003 Nov;28(Suppl 1):19–23.PubMedCrossRefGoogle Scholar
  131. 131.
    Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002 Nov–Dec;12(6):569–572.PubMedGoogle Scholar
  132. 132.
    Vereecken P, Monsieur E, Petein M, et al. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat. 2004 Apr;15(2):120–121.PubMedCrossRefGoogle Scholar
  133. 133.
    Kovach BT, Stasko T. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther. 2005;18:19–27PubMedCrossRefGoogle Scholar
  134. 134.
    Prinz BM, Hafner J, Dummer R, et al. Treatment of Bowen’s disease with imiquimod 5% cream in transplant patients. Transplantation. 2004;77(5):790–791.PubMedCrossRefGoogle Scholar
  135. 135.
    Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27(6):561–564.PubMedCrossRefGoogle Scholar
  136. 136.
    Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol. 2004;29(3):237–239.PubMedCrossRefGoogle Scholar
  137. 137.
    Ulrich C, Stockfelth E. Safety and efficacy of imiquimod 5% cream applied once daily 3 days per week for the treatment of actinic keratoses in immunosuppressed organ transplant recipients-results of a double blinded, European multi-centre study. J Am Acad Dermatol. 2007 Jan P2304 poster presentation.Google Scholar
  138. 138.
    Clayton AS, Stasko T. Treatment of nonmelanoma skin cancer in organ transplant recipients: review of responses to a survey. J Am Acad Dermatol. 2003 Sep;49(3):413–416.PubMedCrossRefGoogle Scholar
  139. 139.
    Torres A, Marra D, Desai TD, et al. Imiquimod 5% cream does not induce tumor skip areas in the topical treatment of basal cell carcinoma. Unpublished data.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Abel Torres
    • 1
  • Tejas Desai
    • 2
  1. 1.Loma Linda Department of DermatologyUniversity School of MedicineLoma LindaUSA
  2. 2.Mohs Micrographic SurgeryLoma Linda UniversityLoma LindaUSA

Personalised recommendations